Researchers have developed an innovative light-based sensor that leverages CRISPR technology to detect ultra-low levels of cancer biomarkers in a single drop of blood, potentially identifying disease before tumors can be seen with conventional imaging. By combining precise DNA targeting with quantum dot signalling, this optical sensor can pick up faint molecular signals that indicate the earliest stages of cancer development. Scientists believe this could lead to minimally invasive, faster and more cost-effective cancer screening tools, with the possibility of dramatically improving survival rates through earlier diagnosis.
